{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T01:32:57Z","timestamp":1778290377877,"version":"3.51.4"},"reference-count":19,"publisher":"Japanese Circulation Society","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Circ J"],"published-print":{"date-parts":[[2018]]},"DOI":"10.1253\/circj.cj-17-0323","type":"journal-article","created":{"date-parts":[[2017,8,18]],"date-time":"2017-08-18T22:13:54Z","timestamp":1503094434000},"page":"148-158","source":"Crossref","is-referenced-by-count":38,"title":["Double-Blind, Randomized, Placebo-Controlled Trial Evaluating the Efficacy and Safety of Eplerenone in Japanese Patients With Chronic Heart Failure (J-EMPHASIS-HF)"],"prefix":"10.1253","volume":"82","author":[{"given":"Hiroyuki","family":"Tsutsui","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kyushu University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Ito","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masafumi","family":"Kitakaze","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine and Development, National Cerebral and Cardiovascular Research Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Issei","family":"Komuro","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, the University of Tokyo Graduate School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toyoaki","family":"Murohara","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Nagoya University Graduate School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tohru","family":"Izumi","sequence":"additional","affiliation":[{"name":"Kitasato University"},{"name":"Niigata Minami Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Sunagawa","sequence":"additional","affiliation":[{"name":"Center for Disruptive Cardiovascular Medicine, Kyushu University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshio","family":"Yasumura","sequence":"additional","affiliation":[{"name":"Cardiovascular Division, Osaka Police Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masafumi","family":"Yano","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine and Clinical Science, Yamaguchi University Graduate School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiro","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Department of Molecular Medicine and Therapeutics, Faculty of Medicine, Tottori University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsutomu","family":"Yoshikawa","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Sakakibara Heart Institute"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takayoshi","family":"Tsutamoto","sequence":"additional","affiliation":[{"name":"Cardiovascular Medicine, Toyosato Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junwei","family":"Zhang","sequence":"additional","affiliation":[{"name":"Clinical Research, Development Japan, Pfizer Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akifumi","family":"Okayama","sequence":"additional","affiliation":[{"name":"Clinical Statistics, Development Japan, Pfizer Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihiko","family":"Ichikawa","sequence":"additional","affiliation":[{"name":"Clinical Research, Development Japan, Pfizer Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiro","family":"Kanmuri","sequence":"additional","affiliation":[{"name":"Clinical Research, Development Japan, Pfizer Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masunori","family":"Matsuzaki","sequence":"additional","affiliation":[{"name":"St. Hill Hospital"},{"name":"Yamaguchi University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"for the J-EMPHASIS-HF Study Group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"330","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al; Randomized Aldactone Evaluation Study Investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. <i>N Engl J Med<\/i> 1999; 341: 709\u2013717.","DOI":"10.1056\/NEJM199909023411001"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, et al; EMPHASIS-HF Study Group. Eplerenone in patients with systolic heart failure and mild symptoms. <i>N Engl J Med<\/i> 2011; 364: 11\u201321.","DOI":"10.1056\/NEJMoa1009492"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Hamaguchi S, Kinugawa S, Tsuchihashi-Makaya M, Goto K, Goto D, Yokota T, et al. Spironolactone use at discharge was associated with improved survival in hospitalized patients with systolic heart failure. <i>Am Heart J<\/i> 2010; 160: 1156\u20131162.","DOI":"10.1016\/j.ahj.2010.08.036"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. McMurray JJ, Krum H, Abraham WT, Dickstein K, K\u00f8ber LV, Desai AS, et al; ATMOSPHERE Committees Investigators. Aliskiren, enalapril, or aliskiren and enalapril in heart failure. <i>N Engl J Med<\/i> 2016; 374: 1521\u20131532.","DOI":"10.1056\/NEJMoa1514859"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, et al; Authors\/Task Force Members. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. <i>Eur Heart J<\/i> 2016; 37: 2129\u20132200.","DOI":"10.1093\/eurheartj\/ehw128"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, et al. 2013 ACCF\/AHA guideline for the management of heart failure: A report of the American College of Cardiology Foundation\/American Heart Association Task Force on practice guidelines. <i>Circulation<\/i> 2013; 128: e240\u2013e327.","DOI":"10.1161\/CIR.0b013e31829e8776"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Swedberg K, Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Shi H, et al; EMPHASIS-HF Study Investigators. Eplerenone and atrial fibrillation in mild systolic heart failure: Results from the EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure) study. <i>J Am Coll Cardiol<\/i> 2012; 59: 1598\u20131603.","DOI":"10.1016\/j.jacc.2011.11.063"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Preiss D, van Veldhuisen DJ, Sattar N, Krum H, Swedberg K, Shi H, et al. Eplerenone and new-onset diabetes in patients with mild heart failure: Results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF). <i>Eur J Heart Fail<\/i> 2012; 14: 909\u2013915.","DOI":"10.1093\/eurjhf\/hfs067"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Eschalier R, McMurray JJ, Swedberg K, van Veldhuisen DJ, Krum H, Pocock SJ, et al; EMPHASIS-HF Investigators. Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and\/or worsening renal function: Analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And Survival Study in Heart Failure). <i>J Am Coll Cardiol<\/i> 2013; 62: 1585\u20131593.","DOI":"10.1016\/j.jacc.2013.04.086"},{"key":"10","unstructured":"10. ICH Steering Committee. Ethnic factors in the acceptability of foreign clinical data (ICH-E5(R1). 1998. http:\/\/www.ich.org\/fileadmin\/Public_Web_Site\/ICH_Products\/Guidelines\/Efficacy\/E5_R1\/Step4\/E5_R1__Guideline.pdf (accessed December 14, 2016)."},{"key":"11","unstructured":"11. World Medical Association. World Medical Association Declaration of Helsinki: Ethical principles for medical research involving human subjects. <i>Bull World Health Organ<\/i> 2001; 79: 373\u2013374."},{"key":"12","unstructured":"12. ICH Steering Committee. Guideline for good clinical practice E6(R1). 1996. https:\/\/www.ich.org\/fileadmin\/Public_Web_Site\/ICH_Products\/Guidelines\/Efficacy\/E6\/E6_R1_Guideline.pdf (accessed February 15, 2017)."},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Shiba N, Watanabe J, Shinozaki T, Koseki Y, Sakuma M, Kagaya Y, et al; CHART Investigators. Analysis of chronic heart failure registry in the Tohoku district: Third year follow-up. <i>Circ J<\/i> 2004; 68: 427\u2013434.","DOI":"10.1253\/circj.68.427"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Shiba N, Shimokawa H. Chronic heart failure in Japan: Implications of the CHART studies. <i>Vasc Health Risk Manag<\/i> 2008; 4: 103\u2013113.","DOI":"10.2147\/VHRM.S2287"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Tsuchihashi-Makaya M, Hamaguchi S, Kinugawa S, Yokota T, Goto D, Yokoshiki H, et al; JCARE-CARD Investigators. Characteristics and outcomes of hospitalized patients with heart failure and reduced vs preserved ejection fraction: Report from the Japanese Cardiac Registry of Heart Failure in Cardiology (JCARE-CARD). <i>Circ J<\/i> 2009; 73: 1893\u20131900.","DOI":"10.1253\/circj.CJ-09-0254"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Petrie MC, Jhund PS, She L, Adlbrecht C, Doenst T, Panza JA, et al; STICH Trial Investigators. Ten-year outcomes after coronary artery bypass grafting according to age in patients with heart failure and left ventricular systolic dysfunction: An analysis of the extended follow-up of the STICH trial (Surgical Treatment for Ischemic Heart Failure). <i>Circulation<\/i> 2016; 134: 1314\u20131324.","DOI":"10.1161\/CIRCULATIONAHA.116.024800"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Tsutamoto T, Wada A, Maeda K, Mabuchi N, Hayashi M, Tsutsui T, et al. Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure. <i>J Am Coll Cardiol<\/i> 2001; 37: 1228\u20131233.","DOI":"10.1016\/S0735-1097(01)01116-0"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Cicoira M, Zanolla L, Rossi A, Golia G, Franceschini L, Brighetti G, et al. Long-term, dose-dependent effects of spironolactone on left ventricular function and exercise tolerance in patients with chronic heart failure. <i>J Am Coll Cardiol<\/i> 2002; 40: 304\u2013310.","DOI":"10.1016\/S0735-1097(02)01965-4"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Chan AK, Sanderson JE, Wang T, Lam W, Yip G, Wang M, et al. Aldosterone receptor antagonism induces reverse remodeling when added to angiotensin receptor blockade in chronic heart failure. <i>J Am Coll Cardiol<\/i> 2007; 50: 591\u2013596.","DOI":"10.1016\/j.jacc.2007.03.062"}],"container-title":["Circulation Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circj\/82\/1\/82_CJ-17-0323\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T13:06:43Z","timestamp":1659359203000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circj\/82\/1\/82_CJ-17-0323\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1253\/circj.cj-17-0323","relation":{},"ISSN":["1346-9843","1347-4820"],"issn-type":[{"value":"1346-9843","type":"print"},{"value":"1347-4820","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018]]}}}